Overview

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

Status:
RECRUITING
Trial end date:
2027-12-29
Target enrollment:
Participant gender:
Summary
The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab.
Phase:
PHASE3
Details
Lead Sponsor:
AstraZeneca
Treatments:
benralizumab